Neurol. praxi. 2015;16(4):227-230

Deliberation about diagnostic overlaps of pregabalin treatment

MUDr. Pavel Dohnal
Centrum pro poruchy spánku Nemocnice České Budějovice, a.s.

Pregabalin(PGB) is a medical substance usefull in more situations. Initialy was used as anticolvulsant medication, but it is used in therapy of neuropatic pain too. Neuropatic pain unlike to somatic pain arises due to gained hypersensibility and hyperexcitability of neurons. PGB increases main inhibitor GABA and decreases quantity of excitate neurotransmitters, which cause decreasing of interneuronal communication. At Generalised anxiety disorder (GAD) is used this effectiveness similarly, where also exhibitions of excessive interneuronal communication is common. PGB in sleeptime increases quantity of NREM3 and simultaneously decreses REM a NREM1, prevents reduction of intracortical, but spinal inhibition too – RLS,PLMD. Inhibition of interneuronal communication is happening at all levels of peripheral and central nervous system. We can involve Epilepsy, also GAD, neuropathy, RLS and PLMD too. Mutual diagnostic overlaps have good response to the treatment with PGB. There is considering synergic effect.

Keywords: pregabalin, neurophy, GAD, RLS, PLMD, interneuronal connectivity

Published: September 19, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Dohnal P. Deliberation about diagnostic overlaps of pregabalin treatment. Neurol. praxi. 2015;16(4):227-230.
Download citation

References

  1. Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med 2014; 370: 621-631. Go to original source...
  2. Coleman P. Pregabalin versus pramipexole for restless legs syndrome; N Engl J Med May 22, 2014; 370: 2049-2051. Go to original source...
  3. MacFarlane BV, Wright A, O'Callaghan J, Benson HAE. Chronic neuropathic pain and its control by drugs. Pharmacol Ther 1997; 75: 1-19. Go to original source...
  4. Garcia-Borreguero D, Larrosa O, Williams AM, Phil M, Albares J, Pascual M, Palacios JC, and Fernandez C. Treatment of restless legs syndrome with pregabalin. A double-blind, placebo-controlled study. Neurology June 8, 2010; 74(23): 1897-1904. Go to original source... Go to PubMed...
  5. Garcia-Borreguero D, Patrick J, DuBrava S, Becker PM, Lankford A, Chen C, Miceli J, Knapp L, Allen RP. Pregabalin versus pramipexole: effects on sleep disturbance in restless legs syndrome. Sleep 2014; 37(4): 635-643. Go to original source... Go to PubMed...
  6. Kasper S, Herman B, Nivoli G,Van Ameringen M, Petralia A, Mandel FS, Baldinetti F, Bandelow B. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind placebo controlled 8-week trial. Int Clin Psychopharmacol 2009; 24(2): 87-96. Go to original source... Go to PubMed...
  7. Mastík J. Antikonvulziva v terapii bolesti - mechanizmy účinku. Neurol. prax, 2008; 1: 39-43.
  8. Roth T, Arnold LM, Garcia-Borreguero D, Resnick M, Clair AG. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev. 2014 Jun; 18(3): 261-271. Go to original source...
  9. Švestka J. Pregabalin - nově dostupné anxiolytikum pro léčbu generalizované úzkostné poruchy; Farmakoterapie 2012(3)..




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.